
CML Today and Tomorrow

Global Survey of Chronic Myeloid Leukemia (CML) Treaters Across 9 Countries and 4 Continents Suggests Many Physicians Are Ambitiously Managing the Disease Despite Its Chronic Nature



References:

Institute. General Information Chronic National Cancer About Myelogenous Leukemia (PDQ) http://www.cancer.gov/cancertopics/pdq/treatment/CML/patient/. Accessed October 2013. 2. Kantarjian, H. The Price of Drugs for Chronic Myeloid Leukemia (CML); A Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Large Group of CML Experts, Blood, 2013;121(22);4439-42, Accessed August 2016, 3, Faderl, S, et al. The Biology of Chronic Myeloid Leukemia. The New England Journal of Medicine. 1999;341(3):164-72. Accessed August 2016. 4. Rea D, et al. Curr Hematol Malig Rep. 2012;7:103-8. 5. Data on file. Novartis Pharma AG. Basel, Switzerland. 6. American Cancer Society. Detailed Guide: CML, http://www.cancer.org/acs/groups/cid/documents/webcontent/003112-pdf.pdf, Accessed May 2014, 7, National CML Society: Monitoring and Tests. http://www.nationalcmlsociety.org/living-cml/monitoring-tests. Accessed March 2015. 8. Hughes, H.P. and Ross, R.M. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016. Advance online publication. doi# 10.1182/blood-2016-01-694265.

NOVARTIS

G-CML-1145654